ArticleBritish journal of haematology2026
Renal amyloidosis prediction in kidney disease patients accompanied by monoclonal gammopathy.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to assess whether routine nephrology examinations could predict renal amyloidosis in kidney disease patients with monoclonal gammopathy. A total of 356 consecutive hospitalized patients in the nephrology department with monoclonal gammopathy performed renal biopsies, including 50 renal amyloidosis patients and 306 non-renal amyloidosis patients, were included after strict filtering. Laboratory and imaging data were collected for each patient. Renal amyloidosis patients exhibited significantly higher 24-h proteinuria and estimated glomerular filtration rate and decreased serum creatinine (SCr), albumin and immunoglobin M, with lower κ light chain and κ/λ ratio in urine and serum. Higher 24-h proteinuria and 24-h microalbuminuria and lower random urine κ/λ ratio, serum κ light chain, serum κ/λ ratio and SCr were significant risk factors for renal amyloidosis. Nomogram model identified albumin, 24-h urinary microalbumin excretion rate, 24-h urine κ light chain, 24-h urine κ/λ ratio and serum IgM as combined predictors of renal amyloidosis (area under the curve 0.781, 95% CI 0.718-0.854). Combined biomarkers (albumin, 24-h urinary microalbumin excretion rate, 24 h urine κ light chain, 24-h urine κ/λ ratio and serum IgM) effectively predicted renal amyloidosis in kidney disease patients with monoclonal gammopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.